See Vilon dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Vilon (Lys-Glu) is a short thymic dipeptide bioregulator studied for its ability to modulate immune cell activity, support T-cell differentiation, and exert broad immunomodulatory effects. As a member of the cytogen class of peptide bioregulators, it is researched in contexts of immune aging and longevity. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when setting up their Vilon reconstitution protocol.
Vilon (Lys-Glu, a synthetic dipeptide) is one of the original short-peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khatskelevich Khavinson, the Russian gerontologist whose decades-long research program built the conceptual framework now collectively known as the Khavinson short-peptide bioregulators. The Khavinson hypothesis — developed across hundreds of Russian-language publications and a smaller English-language record — proposes that very short oligopeptides extracted from young animal tissues, or chemically synthesized to match those sequences, exert organ-specific epigenetic regulation by binding to gene-promoter regions and modulating transcription in the same tissue type they were originally derived from.
Vilon is a synthetic Lys-Glu (KE) dipeptide from the Russian Khavinson short-peptide program, sourced mainly for immune-aging and gerontology research. It ships as a lyophilized powder you reconstitute before use, so the real difference between vendors is what the certificate of analysis (COA) actually shows.
In the Khavinson framework, Vilon is proposed to act through direct binding to gene-promoter DNA in thymic epithelial cells and peripheral lymphocytes, selectively modulating transcription of genes involved in T-cell differentiation, chromatin organisation, and cellular senescence. This proposed direct-DNA-binding mechanism is unconventional and has not been independently characterised outside the Khavinson group.
Russian observational cohorts have reported Vilon (often paired with Thymalin) in elderly immune-decline contexts, with reported improvements in T-cell subset distributions and lymphocyte chromatin-condensation markers; the Lezhava/Khavinson 2004 Bull Exp Biol Med paper is the most-cited specific finding, describing chromatin-decondensation effects on old-age lymphocytes after exposure to Vilon and Livagen. No Western Phase 2 or 3 trial has been registered.
Vilon has a reported half-life of ~30 min (short-peptide estimate), and the dose intervals researchers model most often fall around once daily (in 10–20 day courses). This Khavinson dipeptide (Lys-Glu) clears from plasma within an hour with no buildup; its effect is thought to come from the course as a whole rather than a steady level. It is catalogued under Anti-Aging Peptides on WPA.
10 Vilon reconstitution calculations have been logged by the WPA community. The most common dose entered is 200mcg (4 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 20mg (8 sessions).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.